Format

Send to

Choose Destination
Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12659. Epub 2017 Feb 22.

Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.

Author information

1
Division of Infectious Diseases & Immunology, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA.
2
Division of Cardiac Surgery, Department of Surgery, The Ohio State University (OSU), Columbus, OH, USA.
3
Divsion of Infectious Diseases, Geisinger Health Systems, Danville, PA, USA.
4
Division of Infectious Diseases, Department of Internal Medicine, OSU, Columbus, OH, USA.
5
Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Internal Medicine, OSU, Columbus, OH, USA.

Abstract

Data are limited regarding the use of direct-acting antivirals for treatment of hepatitis C infection post lung transplant, especially in a donor-derived infection. We present a case of a lung transplant recipient with donor-derived hepatitis C that was successfully treated with a 12-week regimen of simeprevir and sofosbuvir. This case reiterates the importance of screening recipients of increased-risk donor organs for disease transmission and the value of early therapy.

KEYWORDS:

direct-acting antivirals; donor-derived infection; hepatitis C; lung transplant

PMID:
28060441
DOI:
10.1111/tid.12659
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center